Skip to main content
Clinical Trials/NCT02356198
NCT02356198
Completed
Not Applicable

Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery: A Prospective Randomized Trial

Mayo Clinic1 site in 1 country209 target enrollmentMarch 2015

Overview

Phase
Not Applicable
Intervention
EXPAREL
Conditions
Conditions Requiring Colorectal Surgery
Sponsor
Mayo Clinic
Enrollment
209
Locations
1
Primary Endpoint
Mean Pain Score
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study is prospective, randomized trial in which EXPAREL TAP block is compared to standard IT opioid administration, in relieving postoperative pain, decreasing length of stay, and use of narcotic medication.

Detailed Description

Primary Objective To assess efficacy of EXPAREL TAP blocks in improving pain scores for 48 hours postoperatively, and in reducing total oral morphine equivalents (OME) use, compared to standard Intrathecal opioid administration (IT). Secondary Objective Assess the length of stay (LOS), postoperative ileus (POI) incidence, and the use of intravenous patient controlled analgesia (PCA) in patients that had EXPAREL TAP blocs compared to IT.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
October 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dorin T. Colibaseanu, M.D.

PI

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • • All patients undergoing elective laparoscopic or open colorectal resections who are eligible for IT
  • Age \>18 years
  • Ability to understand and read English

Exclusion Criteria

  • • Not able or unwilling to sign consent.
  • Currently pregnant or lactating.
  • Patients with chronic pain, requiring daily opiate use at time of surgery.
  • Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
  • Patients requiring emergent surgery.
  • Abdominoperineal resections
  • Any contraindications to neuraxial analgesia (coagulopathy, localized infection at the potential site of injection, pre-existing spinal canal pathology)
  • Patients with a diagnosis of inflammatory bowel disease

Arms & Interventions

TAP block (EXPAREL)

After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.

Intervention: EXPAREL

Intrathecal opioid (IT)

single injection intrathecal hydromorphone analgesia given preoperatively

Intervention: Intrathecal hydromorphone

Outcomes

Primary Outcomes

Mean Pain Score

Time Frame: First 48 hours post operative

Postoperative mean pain score for 48 hours after surgery. Pain was assessed on a 0 to 10 point visual analog scale (VAS), with 0 indicating no pain and 10 indicating severe pain. The mean pain score was summarized as the area under the curve (AUC) of the observed pain score, normalized for the total time of observation.

Total Morphine Milligram Equivalents Use (MME)

Time Frame: First 48 hours post operative

The total cumulative use of opioids administered within 48 hours after surgery. MME is a standard value based on morphine and its potency assigned to all opioids to represent relative potencies.

Secondary Outcomes

  • Use of Intravenous Patient-controlled Analgesia(First 48 hours post-operative)
  • Total Length of Hospital Stay(post-operative to discharge)
  • Number of Participants With Post-operative Ileus(24 hours post-operatively)

Study Sites (1)

Loading locations...

Similar Trials